Immunomedics (IMMU) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Immunomedics (IMMU)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: suite2320	1/5/2005 11:16:01 AM
	Read Replies (1) of 371

MORRIS PLAINS, N.J. (Dow Jones)--Immunomedics Inc. (IMMU) received Food and Drug Administration fast-track designation for its epratuzumab drug in the treatment of a strain of lupus. In a press release Wednesday, the biopharmaceutical company said the agency's decision will speed up the approval application process for the drug to treat moderate to severe forms of systemic lupus erythematosus. In this form, lupus is an autoimmune disease that affects the skin and internal organs such as the heart, lung and kidneys. In autoimmune diseases, the body turns its immune system on itself. The company said this was a significant milestone in the development of the drug for autoimmune diseases and non-Hodgkins Lymphoma. Immunomedics expects to launch a Phase III trial of the drug in the first half of 2005. (MORE) Dow Jones Newswires January 05, 2005 11:12 ET (16:12 GMT)- - 11 12 AM EST 01-05-05 Brought to you by Scottrader, a product of Scottrade Inc

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next